Non-Invasive Monitoring Systems (NIMU) 10-Q 12 Mar 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jan. 31, 2021	Mar. 16, 2021
Cover [Abstract]
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	0000720762
Document Type	10-Q
Document Period End Date	Jan. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		154,810,655
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Current assets
Cash	$ 89	$ 203
Prepaid expenses	26	3
Total current assets	115	206
Total assets	115	206
Current liabilities
Accounts payable and accrued expenses	245	238
Current liabilities - discontinued operations	50	50
Total current liabilities	295	288
Total liabilities	295	288
Commitments and contingencies (Note 8)
Shareholders' deficit
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding	1,548	1,548
Additional paid in capital	26,574	26,574
Accumulated deficit	(28,302)	(28,204)
Total shareholders' deficit	(180)	(82)
Total liabilities and shareholders' deficit	$ 115	$ 206

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Statement of Financial Position [Abstract]
Series B Preferred stock, par value	$ 1	$ 1
Series B Preferred stock, shares authorized	100	100
Series B Preferred stock, shares issued	100	100
Series B Preferred stock, shares outstanding	100	100
Series B Preferred stock, liquidation preference	$ 10	$ 10
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	154,810,655	154,810,655
Common stock, shares outstanding	154,810,655	154,810,655

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Operating costs and expenses
General and administrative	$ 39	$ 47	$ 98	$ 99
Total operating costs and expenses	39	47	98	99
Operating loss	(39)	(47)	(98)	(99)
Loss from continuing operations	(39)	(47)	(98)	(99)
Gain from discontinued operations		4		1
Net loss	$ (39)	$ (43)	$ (98)	$ (98)
Weighted average number of common shares outstanding - Basic and diluted	154,811	154,811	154,811	154,811
Basic and diluted loss per common share from continuing operations	$ 0	$ 0	$ 0	$ 0
Basic and diluted loss per common share from discontinued operations	0	0	0	0
Basic and diluted loss per common share	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Jul. 31, 2019		$ 1,548	$ 26,574	$ (28,041)	$ 81
Balance, beginning shares at Jul. 31, 2019	100	154,810,655
Net loss				(55)	(55)
Balance, ending at Oct. 31, 2019		$ 1,548	26,574	(28,096)	26
Balance, ending shares at Oct. 31, 2019	100	154,810,655
Balance, beginning at Jul. 31, 2019		$ 1,548	26,574	(28,041)	81
Balance, beginning shares at Jul. 31, 2019	100	154,810,655
Net loss					(98)
Balance, ending at Jan. 31, 2020		$ 1,548	26,574	(28,139)	(17)
Balance, ending shares at Jan. 31, 2020	100	154,810,655
Balance, beginning at Oct. 31, 2019		$ 1,548	26,574	(28,096)	26
Balance, beginning shares at Oct. 31, 2019	100	154,810,655
Net loss				(43)	(43)
Balance, ending at Jan. 31, 2020		$ 1,548	26,574	(28,139)	(17)
Balance, ending shares at Jan. 31, 2020	100	154,810,655
Balance, beginning at Jul. 31, 2020		$ 1,548	26,574	(28,204)	(82)
Balance, beginning shares at Jul. 31, 2020	100	154,810,655
Net loss				(59)	(59)
Balance, ending at Oct. 31, 2020		$ 1,548	26,574	(28,263)	(141)
Balance, ending shares at Oct. 31, 2020	100	154,810,655
Balance, beginning at Jul. 31, 2020		$ 1,548	26,574	(28,204)	(82)
Balance, beginning shares at Jul. 31, 2020	100	154,810,655
Net loss					(98)
Balance, ending at Jan. 31, 2021		$ 1,548	26,574	(28,302)	(180)
Balance, ending shares at Jan. 31, 2021	100	154,810,655
Balance, beginning at Oct. 31, 2020		$ 1,548	26,574	(28,263)	(141)
Balance, beginning shares at Oct. 31, 2020	100	154,810,655
Net loss				(39)	(39)
Balance, ending at Jan. 31, 2021		$ 1,548	$ 26,574	$ (28,302)	$ (180)
Balance, ending shares at Jan. 31, 2021	100	154,810,655

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jan. 31, 2021	Oct. 31, 2020	Jan. 31, 2020	Oct. 31, 2019	Jan. 31, 2021	Jan. 31, 2020
Operating activities
Net Loss	$ (39)	$ (59)	$ (43)	$ (55)	$ (98)	$ (98)
Add back: (gain) loss attributable to discontinued operations						(1)
Changes in operating assets and liabilities
Prepaid expenses					(23)	(2)
Accounts payable and accrued expenses					7	(2)
Net cash used in continuing operations					(114)	(103)
Net cash used in operating activities					(114)	(103)
Net decrease in cash from continuing operations					(114)	(103)
Cash, beginning of period		$ 203		$ 353	203	353
Cash, end of period	$ 89		$ 250		$ 89	$ 250

Organization and Business

Organization and Business	6 Months Ended
	Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. ORGANIZATION AND BUSINESS Organization. ® Business. Discontinued Operations. Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at January 31, 2021 and July 31, 2020 and for the three and six months ended January 31, 2021 and 2020. Going Concern 99,000 The Company is seeking potential mergers, acquisitions and strategic collaborations. The Company is also exploring obtaining a promissory note. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Equity Exchange Agreement. On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation. Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3). Use of Estimates. Cash and Cash Equivalents. Income Taxes. Fair Value of Financial Instruments. Loss Contingencies. Related Parties. Recent Accounting Pronouncements.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jan. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. DISCONTINUED OPERATIONS On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The detail of the consolidated balance sheets, the consolidated statements of operations and cash flows for the discontinued operations is as stated below (in thousands): As of January 31, 2021 As of July 31, 2020 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 50 $ 50 Total current liabilities – discontinued operations 50 50 Total liabilities – discontinued operations $ 50 $ 50 For the three For the three For the six For the six General and administrative expenses $ - $ - $ - $ (3 ) Gain on write off of accounts payable - 4 - 4 Gain from discontinued operations $ - $ 4 $ - $ 1 Basic and diluted income (loss) per common share $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) For the three For the three For the six For the six Cash used in operations for discontinued operations: Gain from discontinued operations $ - $ 4 - $ 1 Gain on write off of accounts payable - (4 ) - (4 ) Prepaid expenses - - - 3 Cash used in discontinued operations $ - $ - - $ -

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jan. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	4. STOCK-BASED COMPENSATION The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record stock-based compensation for the three and six months ended January 31, 2021 and 2020. In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of January 31, 2021. As of January 31, 2021, there were no outstanding stock options and there were no unrecognized costs related to outstanding stock options. The Company did not grant any stock options during the three and six months ended January 31, 2021 or 2020.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jan. 31, 2021
Equity [Abstract]
Shareholders' Equity	5. SHAREHOLDERS’ EQUITY The Company has a single class of Preferred Stock. Holders of Series B Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared. No preferred stock dividends were declared for the three and six months ended January 31, 2021 and 2020. The Company did not issue any shares of the Company’s common stock during the three and six months ended January 31, 2021 and 2020.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	6 Months Ended
	Jan. 31, 2021
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Share	6. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the periods ended January 31, 2021 and 2020, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed conversion of preferred stock would be anti-dilutive.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jan. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	7. RELATED PARTY TRANSACTIONS Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrystal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin, serves on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix. The Company expensed $1,200 during the three months ended January 31, 2021 and 2020 and $2,400 during the six months ended January 31, 2021 and 2020 under the cost sharing arrangement. At January 31, 2021 and July 31, 2020, the Company had an accounts payable liability of $800 and $400 under the cost sharing arrangement, respectively. The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the three and six months ended January 31, 2021 and 2020, the Company did not record any rent expense related to the Miami lease. At January 31, 2021 and July 31, 2020 there was no rent payable. The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. COMMITMENTS AND CONTINGENCIES Leases. The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost. COVID-19. Current economic conditions with COVID-19 have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Quarantines would make our ability to look for strategic alternatives more difficult and prospects of borrowing or equity raises would be more challenging. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders. Product Development and Supply Agreement. In September 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date. Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009. Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East. The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through January 31, 2021, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of January 31, 2021, the Company has approximately $41,000 of payables due to Sing Lin. As of January 31, 2021, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million. As of January 31, 2021, the Company had not placed orders sufficient to meet the purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of the date of this filing, Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies. The Company believes that Sing Lin in no longer in business.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Consolidation	Consolidation.
Discontinued Operations	Discontinued Operations. Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3).
Use of Estimates	Use of Estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Income Taxes	Income Taxes.
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Loss Contingencies	Loss Contingencies.
Related Parties	Related Parties.
Recent Accounting Pronouncements	Recent Accounting Pronouncements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jan. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Balance Sheets of Discontinued Operations	The detail of the consolidated balance sheets, the consolidated statements of operations and cash flows for the discontinued operations is as stated below (in thousands): As of January 31, 2021 As of July 31, 2020 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 50 $ 50 Total current liabilities – discontinued operations 50 50 Total liabilities – discontinued operations $ 50 $ 50
Schedule of Statements of Operations for Discontinued Operations	For the three For the three For the six For the six General and administrative expenses $ - $ - $ - $ (3 ) Gain on write off of accounts payable - 4 - 4 Gain from discontinued operations $ - $ 4 $ - $ 1 Basic and diluted income (loss) per common share $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 )
Schedule of Cash Flows of Discontinued Operations	For the three For the three For the six For the six Cash used in operations for discontinued operations: Gain from discontinued operations $ - $ 4 - $ 1 Gain on write off of accounts payable - (4 ) - (4 ) Prepaid expenses - - - 3 Cash used in discontinued operations $ - $ - - $ -

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Jul. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses from continuing operation	$ (39)	$ (47)	$ (98)	$ (99)
Accumulated deficit	(28,302)		(28,302)		$ (28,204)
Cash	89		89		$ 203
Working capital (deficit)	$ 180		$ 180

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Accounting Policies [Abstract]
Cash	$ 89	$ 203
Cash equivalents

Discontinued Operations - Sched

Discontinued Operations - Schedule of Balance Sheets of Discontinued Operations (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Accounts payable and accrued expenses	$ 50	$ 50
Total current liabilities - discontinued operations	50	50
Total liabilities - discontinued operations	$ 50	$ 50

Discontinued Operations - Sch_2

Discontinued Operations - Schedule of Statements of Operations for Discontinued Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
General and administrative expenses				$ (3)
Gain on write off of accounts payable		4		4
Gain from discontinued operations		$ 4		$ 1
Basic and diluted income (loss) per common share	$ 0	$ 0	$ 0	$ 0

Discontinued Operations - Sch_3

Discontinued Operations - Schedule of Cash Flows of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Gain from discontinued operations		$ 4		$ 1
Gain on write off of accounts payable		(4)		(4)
Prepaid expenses				3
Cash used in discontinued operations

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Nov. 30, 2010
Stock based compensation
Stock options, outstanding
Unrecognized costs related to outstanding stock options
Number of stock options granted
2011 Stock Incentive Plan [Member]
Number of stock option awards
2011 Stock Incentive Plan [Member] | Maximum [Member]
Maximum number of shares authorized for issuance under the plan			4,000,000

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Dividends, preferred stock
Stock issued during the period
Preferred Stock Series B [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value	$ 100		$ 100
Dividends payable amount per share	$ 10		$ 10

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Details Narrative) - shares	6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 02, 2008	Feb. 29, 2016	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Jul. 31, 2020
Dr. Phillip Frost [Member]
Lease term	5 years
Lease expired date	Dec. 31, 2012
Rental payments	$ 1,250
Reduced amount in rental payments		$ 0
Rent expense
Dr. Phillip Frost [Member] | Minimum [Member]
Beneficial ownership percentage	10.00%
Cost Sharing Arrangement [Member]
Costs and expenses related party			1,200	$ 1,200	2,400	$ 2,400
Accounts payable related parties			$ 800		$ 800		$ 400

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Sep. 30, 2007	Jan. 31, 2021
Lease expiration, date		2012
Purchase obligation		$ 13,900
Sing Lin Technologies [Member]
Payments to suppliers		1,700
Payables to customers		41
Product Development and Supply Agreement [Member] | Sing Lin Technologies Co. Ltd. [Member]
Manufacturing costs	$ 471
Tooling cost	150
Payments on approval of product prototype concepts and designs	$ 150
Purchase obligations commitments	The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement.
Product Development and Supply Agreement [Member] | Exer-Rest units [Member]
Purchase obligation, due in next twelve months		2,600
Purchase obligation, due in second year		4,100
Purchase obligation, due in third year		$ 8,800